Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19434948 | 0.91 | GPR119 (0.55) | GPR119CYP3A4CYP2C19CNR2GPR183 | |
| SCHEMBL19434778 | 0.88 | GPR119 (0.42) | GPR119CYP3A4CYP2C19CNR2GPR183 | |
| SCHEMBL29850886 | 0.86 | GPR119 (0.52) | GPR119CYP3A4CYP2C19CNR2GPR183 | |
| SCHEMBL19434844 | 0.86 | GPR119 (0.52) | GPR119CYP3A4CYP2C19CNR2GPR183 | |
| SCHEMBL19454580 | 0.85 | CNR2 (0.51) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL19434924 | 0.85 | GPR119 (0.43) | GPR119CYP3A4CYP2C19CNR2GPR183 | |
| SCHEMBL19434851 | 0.84 | CNR2 (0.46) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL29504481 | 0.84 | CNR2 (0.46) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL19435013 | 0.84 | CNR2 (0.42) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL29504621 | 0.84 | CNR2 (0.42) | GPR119CYP3A4CYP2C19CNR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440087-B1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2022-08-10 | — | — | EP | claimed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | claimed |
| EP-3440087-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2019-02-13 | — | — | EP | claimed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | claimed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | claimed |
| EP-3440087-B1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2022-08-10 | — | — | EP | disclosed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| EP-3440087-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2019-02-13 | — | — | EP | disclosed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | GPR119 1/4885CYP3A4 2006/4885CYP2C19 1094/4885 |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | GPR119 1/4885CYP3A4 2006/4885CYP2C19 1094/4885 |
| US-10919915-B2 | Compounds as GPR119 agonists | GPR119, GPR84, GPR65 | GPR119 1/4885CYP3A4 1458/4885CYP2C19 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.